uniQure (NASDAQ:QURE - Get Free Report) CFO Christian Klemt sold 1,796 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.55, for a total value of $13,559.80. Following the transaction, the chief financial officer now directly owns 166,713 shares of the company's stock, valued at $1,258,683.15. The trade was a 1.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
uniQure Trading Up 109.6 %
QURE opened at $15.30 on Wednesday. uniQure has a one year low of $3.73 and a one year high of $17.39. The stock has a market capitalization of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. The business's 50 day moving average price is $6.42 and its 200 day moving average price is $6.15. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts' consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analysts' expectations of $2.73 million. As a group, equities research analysts expect that uniQure will post -3.74 EPS for the current year.
Wall Street Analysts Forecast Growth
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
A number of research analysts have weighed in on QURE shares. HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday. Royal Bank of Canada cut their price objective on shares of uniQure from $16.00 to $14.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Raymond James upgraded uniQure from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $20.00 to $52.00 in a report on Tuesday. StockNews.com upgraded uniQure to a "sell" rating in a report on Wednesday. Finally, The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a "neutral" rating on the stock in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.33.
Get Our Latest Analysis on uniQure
Institutional Trading of uniQure
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC raised its position in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 2,306 shares during the period. China Universal Asset Management Co. Ltd. raised its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Geode Capital Management LLC raised its position in uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company's stock valued at $2,509,000 after purchasing an additional 6,362 shares during the period. American Century Companies Inc. raised its position in uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company's stock valued at $303,000 after purchasing an additional 8,642 shares during the period. Finally, RTW Investments LP purchased a new stake in uniQure in the third quarter valued at approximately $49,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
